CareLit · DOI-Nachweis · Pneumologie
Safety of once-daily tiotropium and olodaterol fixed-dose combination via the Respimat in chronic obstructive pulmonary disease in two 1-year studies
DOI 10.1055/s-0035-1544638
Bibliografische Angaben
Nachweis in CareLit
Autor:innenR Buhl, R Abrahams, L Bjermer, E Derom, M Fležar, J Hébert, A Veale, L Groenke, A Hamilton, K Tetzlaff, L Korducki, H Huisman, S Waitere-Wijker, L McGarvey
ZeitschriftPneumologie
Ausgabe02/2015
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Introduction: The fixed-dose combination (FDC) of tiotropium (T), a once-daily long-acting muscarinic antagonist, and olodaterol (O), a once-daily long-acting ß2-agonist, is currently being evaluated in chronic obstructive pulmonary disease (COPD). Two 52-week, Phase III replicate pivotal studies were conducted to assess the efficacy and safety of FDCs of T and O (T+O) delivered via Respimat Soft Mist inhaler in pat…
Zitieren
Zitierempfehlung
R Buhl, R Abrahams, L Bjermer, E Derom, M Fležar, J Hébert, A Veale, L Groenke, A Hamilton, K Tetzlaff, L Korducki, H Huisman, S Waitere-Wijker, L McGarvey (2015) Safety of once-daily tiotropium and olodaterol fixed-dose combination via the Respimat in chronic obstructive pulmonary disease in two 1-year studies. Pneumologie (02). https://doi.org/10.1055/s-0035-1544638
Mit CareLit weiterarbeiten